Search

ACR Convergence 2024 marks UCB's first presentation of data in psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) since the recent approvals of BIMZELX(bimekizumab-bkzx) in these indications [...]

(GLOBE NEWSWIRE via COMTEX) -- MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody(R) sonelokimab in patients with active psoriatic arthritis - Two trials for active psoriatic arthritis (PsA) [...]

2025 JAN 1 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New study results on psoriatic arthritis have been published. According to news reporting out of [...]

2024 DEC 13 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Research findings on psoriatic arthritis are discussed in a new report. According to [...]

2024 NOV 29 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on psoriatic arthritis is the subject of a new report. According [...]

First Phase 3b study in psoriatic arthritis to evaluate the superiority of an IL-17A and IL-17F inhibitor to an IL-23 inhibitor This first head-to-head study in psoriatic arthritis to use [...]

2024 SEP 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on psoriatic arthritis is now available. According to news reporting [...]

2024 AUG 23 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on psoriatic arthritis have been published. According to news reporting [...]

-- First indications of RINVOQ (upadacitinib) for pediatric patients two years of age and older[sup.1] -- RINVOQ is now approved for eight indications across immune-mediated inflammatory diseases[sup.1] NORTH CHICAGO, Ill., [...]

(GlobeNewswire) - MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the [...]

(GLOBE NEWSWIRE via COMTEX) -- MoonLake announces significant improvements with Nanobody(R) sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day - Positive [...]

2024 JUL 10 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in Skin Diseases and Conditions - Nail Diseases and Conditions. According [...]

The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 (15 mg and 30 mg Respectively) Achieving At Least an ACR 20 Response Compared to [...]

Takeda announced on 7 Nov 2023 that the company will present positive results from its randomized, double-blind, placebo-controlled, Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in patients with active psoriatic arthritis. These data (Abstract L12) will be presented on 14 Nov 2023 as part of the late-breaking poster session from 9:00 AM - 11:00 AM PT at the American College of Rheumatology (ACR) Convergence 2023 in San Diego, CA, US. The study met its primary endpoint with a statistically significant proportion of patients, 53.3% (15 mg) and 54.2% (30 mg), treated with TAK-279 achieving at least an American College of Rheumatology 20 (ACR 20) response compared to 29.2% in the placebo arm at week 12 (p = 0.002). The safety and tolerability profile of TAK-279 in the trial was consistent with that observed in the Phase 2b psoriasis study. There was no statistically significant difference in ACR 20 seen in the TAK-279 5 mg arm (35.2%) compared to the placebo arm (29.2%). The study also demonstrated improvements in key secondary endpoints: At 15 mg and 30 mg of TAK-279, 26.7% (p=0.005) and 26.4% (p=0.009) of patients achieved ACR 50 response compared to 9.7% of patients on placebo. A numerically higher proportion of patients treated with TAK-279 15 mg (14.7%) and 30 mg (13.9%) achieved ACR 70 compared to those on placebo (5.6%). In patients with a body surface area (BSA) greater than or equal to 3% at baseline, Psoriasis Area and Severity Index (PASI) 75 was achieved in a greater proportion of patients treated with TAK-279 [45.7% (30 mg), 28.3% (15 mg) and 25.6% (5 mg); p = 0.002, 0.101 and 0.186 vs placebo (15.4%)]. In patients with Physician Global Assessment of Psoriasis (PGA-PsO) at least 2 at baseline, a greater proportion of patients treated with TAK-279 30 mg achieved a PGA-PsO score of 0 (clear) or 1 (almost clear) and at least a 2-point improvement from baseline compared to placebo [32.8% (30 mg), 20.6% (15 mg), 20.4% (5 mg) vs 15.8% (placebo); p = 0.034 for 30 mg]. Reductions were observed in mean change from baseline in the tender joint count and swollen joint count in all groups, with higher reductions with the 15 mg and 30 mg doses compared to placebo and 5 mg TAK-279. Minimal disease activity (MDA) response rates were higher in TAK-279 15 mg and 30 mg groups than in placebo [28.0% (15 mg) and 29.2% (30 mg); p = 0.017 and 0.014 vs placebo (12.5%)]. The most common treatment-emergent adverse events (TEAEs) in patients who received TAK-279 5 mg, 15 mg, or 30 mg versus placebo, respectively, were nasopharyngitis (8.5%, 9.3%, 9.7%, 4.2%), upper respiratory tract infections (11.3%, 4%, 9.7%, 2.8%), headache (2.8%, 8.0%, 5.6%, 4.2%) and rash (4.2%, 8%, 5.6%, 0%). No opportunistic infections, major adverse cardiovascular events or differences in mean laboratory parameters of interest were observed, compared with placebo. Original source: Takeda, website: http://www.takeda.com/, Copyright Takeda Pharmaceutical Company Limited 2023., research and development; antiarthritics; enzyme inhibitors; [...]

2024 MAR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- A new study on psoriatic arthritis is now available. According to news reporting out of [...]

2024 JAN 3 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on biologics. According to news originating from Osaka, Japan, by NewsRx [...]

2023 DEC 8 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on psoriatic arthritis is the subject of a new report. According [...]

2023 NOV 29 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in psoriatic arthritis. According to news reporting from Strasbourg, France, by [...]

Byline: By, Jessica Knibbs Psoriatic arthritis is a type of arthritis that affects people who are susceptible to the skin condition psoriasis. The condition can affect anyone, including children, and [...]

2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Research findings on psoriatic arthritis are discussed in a new report. According to [...]

UCB, a global biopharmaceutical company, announced on 27 Apr 2023 that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions recommending granting marketing authorization for bimekizumab in the European Union (EU) for the treatment of adults with active axial spondyloarthritis (axSpA) and for adults with active psoriatic arthritis (PsA). AxSpA is an indication that spans both non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axSpA (r-axSpA). If approved by the European Commission (EC), these would represent the second and third indications for bimekizumab in the EU, following its initial approval for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy in Aug 2021. In active PsA, the CHMP recommended approval of bimekizumab alone or in combination with methotrexate, for the treatment of adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs. The CHMP opinion is based on data from the Phase 3 BE COMPLETE and BE OPTIMAL studies recently published in The Lancet. The two studies met their primary and all ranked secondary endpoints with statistical significance at week 16.2, Long-term data from BE OPTIMAL showed that bimekizumab demonstrated sustained responses to week 52. In active axSpA, the CHMP recommended approval of bimekizumab for the treatment of adults with active nr-axSpA with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs, and for the treatment of adults with active AS (r-axSpA) who have responded inadequately or are intolerant to conventional therapy. The positive CHMP opinion is based on data from the Phase 3 BE MOBILE 1 and BE MOBILE 2 studies, recently published in Annals of the Rheumatic Diseases. The two studies met their primary and all ranked secondary endpoints with statistical significance at week 16.5 Long-term data from both studies showed that bimekizumab demonstrated sustained responses to week 52. In all four studies (BE OPTIMAL, BE COMPLETE, BE MOBILE 1 and BE MOBILE 2) the safety data were consistent with previous studies with no new observed safety signals. The CHMP positive opinions on bimekizumab in active PsA and active axSpA will be referred to the EC, which will deliver a final decision within approximately two months. The marketing authorization will be valid in all member states of the European Union as well as Iceland, Norway, Northern Ireland and Liechtenstein. Bimekizumab is currently approved in the European Union for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Original source: UCB, website: http://www.ucb.com/, Copyright UCB SA 2023., regulations and rulings; research and development; antiarthritics; bimekizumab; monoclonal antibodies; psoriasis treatments; therapeutic antibodies; [...]

AbbVie Korea said on Tuesday that its psoriasis drug Skyrizi (ingredient: risankizumab) will be reimbursed as a treatment from March 1, for active and progressive psoriatic arthritis in adult patients [...]

2023 JUN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- According to news reporting based on a preprint abstract, our journalists obtained the [...]

New York, USA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Psoriatic Arthritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain The prevalence of Psoriatic [...]

Two articles report results from the Phase 3 BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab, an investigational, selective inhibitor of IL-17A and IL-17F, in patients with psoriatic arthritis BRUSSELS [...]

SPRING HOUSE: Janssen Pharmaceutical Companies of Johnson & Johnson has issued the following news release: The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of [...]

The Janssen Pharmaceutical Companies of Johnson & Johnson announced on 10 Nov 2022 a new post-hoc analysis of the Phase 3 DISCOVER-2 study that show early (week 8) clinical improvements of most measures (joint and skin disease, enthesitis and dactylitis) in adult patients with active psoriatic arthritis (PsA) treated with Tremfya (guselkumab) were associated with meaningful improvements in health-related quality of life (HRQoL) (measured by EQ-5D)b from year one (week 52) through year two (week 100). Tremfya is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the US for adults with active PsA and adults with moderate to severe plaque psoriasis (PsO). In a separate post-hoc analysis of DISCOVER-2, clinically meaningful improvements in fatigue [measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)] observed at one year in Tremfya-treated patients were enhanced through two years, resulting in greater proportions of patients achieving normative FACIT-F levels. These new analyses of DISCOVER-2 data presented at the 2022 American College of Rheumatology (ACR) Convergence meeting, taking place in Philadelphia, PA and virtually, 10-14 Nov 2022, show: In DISCOVER-2, biologic-naive patients with active PsA who were randomized to Tremfya: Early (week 8) response in distinct active PsA domains differentially impacted specific components of HRQoL (eg EQ-5D, SF-36, DLQI)b,e over two years versus placebo. Statistically significant improvements in overall and physical HRQoL were observed among early clinical responders across several active PsA domains including joint and skin disease, enthesitis, and dactylitis, versus placebo. Despite differences in HRQoL observed among early clinical responders and non-early responders, non-early responders also saw benefit in long-term HRQoL with Tremfya versus placebo. In DISCOVER-2 patients with active PsA and elevated measures of fatigue: Tremfya provided statistically significant benefit over placebo for reducing fatigue as early as week 8 (nominal P-values). FACIT-F scores continued to improve between week 24 and week 52 in Tremfya-treated patient groups. The clinically meaningful improvements in fatigue seen at week 52 in Tremfya-treated patients were further enhanced through week 100, resulting in greater proportions of patients achieving normative FACIT-F levels. Improvement of greater than or equal to 2 points in FACIT-F by week 8 predicted clinically meaningful improvement of greater than or equal to 4 points at week 100. Early targets in FACIT-F levels achieved at 8 weeks of Tremfya treatment were identified as a potential predictor of later response. Original source: Johnson & Johnson, website: http://www.jnj.com/, Copyright Johnson & Johnson Services Inc 2022., research and development; antiarthritics; guselkumab; monoclonal antibodies; therapeutic antibodies; Tremfya; Janssen Pharmaceutical Companies; Johnson & [...]

Post-hoc analysis of DISCOVER-2 Phase 3 data suggest active psoriatic arthritis patients with week 8 response to TREMFYA showed meaningful improvements in health-related quality of life at week 100, compared [...]

LOS ANGELES: ACELYRIN, INC has issued the following news release: ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today [...]

Newly reported data in key disease manifestations including dactylitis and nail lesions to be presented at the American College of Rheumatology (ACR) Convergence 2022 Combined with previously reported differentiated data [...]

ZUG, Switzerland: MoonLake Immunotherapeutics AG has issued the following news release: MoonLake Immunotherapeutics AG ('MoonLake'), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced U.S. [...]

NORTH CHICAGO: AbbVie has issued the following news release: AbbVie ( NYSE: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI(r) (risankizumab, 150 [...]

- Analyses included 100-week efficacy and safety data from the four-year, open-label extension period of KEEPsAKE 1 and 2 evaluating SKYRIZI in patients with active psoriatic arthritis1 - Ongoing treatment [...]

- Analyses included 100-week efficacy and safety data from the four-year, open-label extension period of KEEPsAKE 1 and 2 evaluating SKYRIZI in patients with active psoriatic arthritis[sup.1] - Ongoing treatment [...]

2023 APR 7 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Autoimmune Diseases and Conditions - Psoriatic Arthritis have been [...]